NASDAQ · PTGX
Protagonist Therapeutics, Inc.
$144.34+$2.20 (+1.55%)
Protagonist Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.24% below the high.
Loading market information…
NASDAQ · ODTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Odyssey Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Odyssey Therapeutics, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$1.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Odyssey Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $40.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$144.34+$2.20 (+1.55%)
Protagonist Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.24% below the high.
$98.96-$0.79 (-0.79%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.18% below the high.
$96.65+$0.68 (+0.71%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.33% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
$7.95-$0.01 (-0.13%)
AgomAb Therapeutics N.V. American Depositary Shares’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
